Daiichi Sankyo Co Ltd 2009 SR
The report details the Daiichi Sankyo Group's CSR performance for fiscal 2008, emphasizing the implementation of the Plan-Do-Check-Act (PDCA) cycle. Key highlights include the strategic integration of Ranbaxy Laboratories and U3 Pharma to bolster global infrastructure. The company achieved 'zero emissions' at its domestic sites, reaching a final waste disposal rate of 0.89%. Social initiatives focused on improving Medical Representative (MR) capabilities and developing treatments for rare disorders. While domestic CO2 emissions were reduced, total global emissions rose due to business expansion and the Group's commitment to a 'Hybrid Business Model' to serve diverse global medical needs.
Company: Daiichi Sankyo Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2009
Type: SR
Pages: 62
Daiichi Sankyo Co Ltd
The report details the Daiichi Sankyo Group's CSR performance for fiscal 2008, emphasizing the implementation of the Plan-Do-Check-Act (PDCA) cycle. Key highlights include the strategic integration of Ranbaxy Laboratories and U3 Pharma to bolster global infrastructure. The company achieved 'zero emissions' at its domestic sites, reaching a final waste disposal rate of 0.89%. Social initiatives focused on improving Medical Representative (MR) capabilities and developing treatments for rare disorders. While domestic CO2 emissions were reduced, total global emissions rose due to business expansion and the Group's commitment to a 'Hybrid Business Model' to serve diverse global medical needs.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2009
Reporting Period
Apr 1, 2008 - Mar 31, 2009
Fiscal Year
2008
Published
Sep 1, 2009
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Total Waste
Women in Management
Employees